Mnemo Therapeutics
Massamba Mbacke NDIAYE has worked in a variety of roles since 2013. From 2013 to 2016, they worked as a Hotliner Service technician for b2s - Business Support Services. Massamba Mbacke then worked as a Stagiaire at the Institut du Physique du Globe de Paris in 2015. From 2016 to 2022, they worked as a PhD ATER, Chercheur doctorant, and Stagiaire at ESPCI, and is currently working as a Scientist for Proteomics and Immunopeptidomics Analysis at Mnemo Therapeutics.
Massamba Mbacke NDIAYE has a diverse educational background. From 2009 to 2012, they obtained a Licence in Génie de l'Eau et de l'Environnement from the Université Hassan 2: Faculté des Sciences et Techniques. From 2014 to 2015, they completed a Master 2 (M2) in SAGE: Systèmes aquatiques et Gestion de l'Eau from the Ecole Nationale des Ponts et Chaussées. Massamba Mbacke then obtained a master in chimie analytique, physique et théorique, spécialité chimie analytique from the Pierre and Marie Curie University from 2015 to 2016. Finally, from 2016 to 2019, Massamba Mbacke NDIAYE completed a Docteur en chimie analytique from ESPCI Paris - PSL, with a focus on biotechnologie, protéomique, spectrométrie de masse, and microfluidique.
This person is not in any offices
Mnemo Therapeutics
1 followers
Mnemo Therapeutics is a biotechnology company focused on developing powerful cell therapies that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform, a groundbreaking drug discovery engine, leverages a new class of antigens with greater tumor specificity and a suite of technologies to significantly improve T cell memory, persistence, and sensitivity. The result is dramatic improvement in the body’s immune response to overcome disease. Mnemo is built by a transatlantic team of scientists and biotech leaders united in their mission to create the most powerful immune therapies to deliver accessible cures for all patients in need.